par2 activating matriptase (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
par2 activating matriptase
Par2 Activating Matriptase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+matriptase/Recombinant+Human+Matriptase%2FST14+Catalytic+Domain%2C+CF/pmc13098787-140-26-30
Average 95 stars, based on 30 article reviews
Par2 Activating Matriptase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+matriptase/Recombinant+Human+Matriptase%2FST14+Catalytic+Domain%2C+CF/pmc13098787-140-26-30
Average 95 stars, based on 30 article reviews
par2 activating matriptase - by Bioz Stars,
2026-11
95/100 stars
Images
1) Product Images from "Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease"
Article Title: Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease
Journal: Pain Reports
doi: 10.1097/PR9.0000000000001446
Figure Legend Snippet: Colonic PAR2 activation by 2F elicits LSN responses that are mediated by endosomal internalization, PKA and PKC. (A) Experimental framework for LSN recordings showing a cannulated colon in a recording chamber with the LSN aspirated into a suction electrode. (B) Representative action potentials recorded from LSN afferent fiber prestimulation. (C and D) 100 µM 2F application elicits LSN responses illustrated by (C) action potential traces prestimulation and 15 minutes poststimulation and (D) change in LSN firing rate over time after stimulation via the luminal inflow (vertical dotted line). 2F-stimulation increased LSN firing (E and F). Timeline and peak change in firing rate after 100 µM 2F application (vertical dotted line) in tissue pretreated with (E) 50 µM PitStop2 (PS2) inhibitor for endosomal internalization or negative control PitNot2 (PN2) and (F) 100 µM H-89 dihydrochloride (H-89) and bisindolylmaleimide (GFX), PKA and PKC inhibitors or DMSO vehicle. (E) PS2 as well as separate and simultaneous pretreatment with H-89 and GFX reduced the peak response to 2F. (D and E) Independent samples t test comparing the peak change in firing rate (N = 5–9). (F) One-way ANOVA with post-hoc FDR-corrected independent samples t test (N = 5–6). * P < 0.05, ** P < 0.01, *** P < 0.001 **** P < 0.0001. Data are presented as mean ± SD. LSN, lumbar splanchnic nerve; PAR2, protease-activated receptor 2; PKA, protein kinase A; PKC, protein kinase C.
Techniques Used: Activation Assay, Negative Control
Figure Legend Snippet: PAR2 activation in the colon by 2F sensitizes LSN responses to mechanical and chemical stimulation of the colon via endosomal internalization, PKA and PKC. LSN action potential firing after mechanical distention: gradually increasing intraluminal pressure from 0 to 80 mm Hg, and chemical application: 1 mM cinnamaldehyde and 1 µM capsaicin are illustrated in (A). (B) Responses to distention were quantified through the change in firing rate over increasing discrete pressure values. (C and D) Responses to chemical stimuli were quantified through the change in firing rate over time after application (vertical dotted line). 100 µM 2F stimulation, but not vehicle control, elicited sensitization of the LSN to (B) distention, (C) cinnamaldehyde, and (D) capsaicin. Pretreatment with PS2 before 2F stimulation reduced subsequent LSN responses to distention, cinnamaldehyde, and capsaicin compared with PN2. Pretreatment with H-89 and GFX, applied either simultaneously or individually, also reduced subsequent peak LSN responses to distention, cinnamaldehyde, and capsaicin compared with DMSO vehicle. (B–D) Independent samples t tests and one-way ANOVA with post-hoc FDR-corrected independent samples t test (N = 5–9). * P < 0.05, ** P < 0.01, **** P < 0.0001. Data are presented as means ± SD. LSN, lumbar splanchnic nerve; PAR2, protease-activated receptor 2; PKA, protein kinase A; PKC, protein kinase C.
Techniques Used: Activation Assay, Control
Related Articles
Purification:Article Title: Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa. Article Snippet: Factor XIIa (FXIIa) is a promising target for developing new drugs that prevent thrombosis without causing bleeding complications.. A native cyclotide (MCoTI-II) is gaining interest for engineering FXIIatargeted anticoagulants as this peptide inhibits FXIIa but not other coagulation proteases.. Here, we engineered the native biosynthetic cyclization loop of MCoTI-II (loop 6) to generate improved FXIIa inhibitors. Article Title: Inducible monovalent antigen binding protein Article Snippet: Purified plasmid DNA was transfected into Expi293 cells in accordance with Expi293 Expression System Kit (ThermoFisher) protocols, and maintained for 4-6 days post transfection. .. Purified exemplary monovalent antibodies were either proteolytically activated with 40 nM Clinical Proteomics:Article Title: Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa. Article Snippet: Factor XIIa (FXIIa) is a promising target for developing new drugs that prevent thrombosis without causing bleeding complications.. A native cyclotide (MCoTI-II) is gaining interest for engineering FXIIatargeted anticoagulants as this peptide inhibits FXIIa but not other coagulation proteases.. Here, we engineered the native biosynthetic cyclization loop of MCoTI-II (loop 6) to generate improved FXIIa inhibitors. Recombinant:Article Title: Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa. Article Snippet: Factor XIIa (FXIIa) is a promising target for developing new drugs that prevent thrombosis without causing bleeding complications.. A native cyclotide (MCoTI-II) is gaining interest for engineering FXIIatargeted anticoagulants as this peptide inhibits FXIIa but not other coagulation proteases.. Here, we engineered the native biosynthetic cyclization loop of MCoTI-II (loop 6) to generate improved FXIIa inhibitors. Article Title: Autophagy of Candida albicans cells after the action of earthworm Venetin-1 nanoparticle with protease inhibitor activity Article Snippet: Recombinant bovine trypsin was purchased from Sigma-Aldrich (Germany) and chymotrypsin was provided by Bachem (Germany). .. Article Title: Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. Article Snippet: Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine Caroline M. Kopruszinski, John E. Linley, Peter Thornton, Alison S. Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W. Dodick, Claire Dobson, Tharani Chessell, Frank Porreca and Iain Chessell Article Title: Inducible monovalent antigen binding protein Article Snippet: Purified plasmid DNA was transfected into Expi293 cells in accordance with Expi293 Expression System Kit (ThermoFisher) protocols, and maintained for 4-6 days post transfection. .. Purified exemplary monovalent antibodies were either proteolytically activated with 40 nM Article Title: Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine Article Snippet: Thrombin from human plasma (Sigma) was used to activate PAR1 where detailed and diluted in PBS + 0.1% BSA to generate a 10 μM stock solution prior to final dilution in assay buffer. .. other:Article Title: Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry. Article Snippet: All measurements were performed using a Fluostar Omega microplate reader (BMG Labtech, Germany) and 96-well black plates (BRAND, Germany). Concentration Assay:Article Title: Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. Article Snippet: Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine Caroline M. Kopruszinski, John E. Linley, Peter Thornton, Alison S. Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W. Dodick, Claire Dobson, Tharani Chessell, Frank Porreca and Iain Chessell Article Title: Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine Article Snippet: Thrombin from human plasma (Sigma) was used to activate PAR1 where detailed and diluted in PBS + 0.1% BSA to generate a 10 μM stock solution prior to final dilution in assay buffer. .. Saline:Article Title: Inducible monovalent antigen binding protein Article Snippet: Purified plasmid DNA was transfected into Expi293 cells in accordance with Expi293 Expression System Kit (ThermoFisher) protocols, and maintained for 4-6 days post transfection. .. Purified exemplary monovalent antibodies were either proteolytically activated with 40 nM Control:Article Title: Inducible monovalent antigen binding protein Article Snippet: Purified plasmid DNA was transfected into Expi293 cells in accordance with Expi293 Expression System Kit (ThermoFisher) protocols, and maintained for 4-6 days post transfection. .. Purified exemplary monovalent antibodies were either proteolytically activated with 40 nM |
